<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04335669</url>
  </required_header>
  <id_info>
    <org_study_id>NBG-19-01; SWEBCG 19-01</org_study_id>
    <nct_id>NCT04335669</nct_id>
  </id_info>
  <brief_title>NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC</brief_title>
  <official_title>A Translational Randomized Phase III Study Exploring the Effect of the Addition of Capecitabine to Carboplatine Based Chemotherapy in Early &quot;Triple Negative&quot; Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lund University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swedish Breast Cancer Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Danish Breast Cancer Cooperative Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Finnish Breast Cancer Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Icelandic Breast Cancer Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lund University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary aim: Pathological complete response rate after preoperative chemotherapy is the
      primary end-point of the study, which will be evaluated by comparing the effects of
      neoadjuvant administration of a carboplatin-based treatment and treatment adding capecitabine
      on Pathological Complete Response (pCR).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary aim: Pathological complete response rate after preoperative chemotherapy is the
      primary end-point of the study, which will be evaluated by comparing the effects of
      neoadjuvant administration of a carboplatin-based treatment and treatment adding capecitabine
      on pCR.

      Primary translational aim: To investigate if the effects of the treatments depend on
      homologous repair deficiency (HRD)-status. More specifically, the aim is to test for
      differential effect of the two treatments on pCR for HRD-negative (HRD low and intermediate
      by oncoscan) and HRD-positive (HRD high by oncoscan) patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 20, 2019</start_date>
  <completion_date type="Anticipated">December 25, 2032</completion_date>
  <primary_completion_date type="Anticipated">June 25, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological complete response rate.</measure>
    <time_frame>Immediately after surgery</time_frame>
    <description>Rate of pathological complete response, allowing residual dcis, at surgery after preoperative chemotherapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary translational outcome.</measure>
    <time_frame>Immediately after surgery</time_frame>
    <description>Pathological complete response rate, allowing residual dcis, stratified for homologous repair deficiency.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Invasive Disease Free Survival (IDFS)</measure>
    <time_frame>Throughout the study, an average of 3 years</time_frame>
    <description>Invasive disease-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Throughout the study, an average of 5 years</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breast Cancer Specific Survival (BCSS)</measure>
    <time_frame>Throughout the study, an average of 3 years</time_frame>
    <description>Breast cancer specific survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant Recurrence Free Survival (DRFS)</measure>
    <time_frame>Throughout the study, an average of 3 years</time_frame>
    <description>Distant recurrence free survival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose intensity</measure>
    <time_frame>Immediately after surgery</time_frame>
    <description>Actual dosis/dosis per protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity according to CTCAE version 5.0</measure>
    <time_frame>Immediately after surgery</time_frame>
    <description>Rate of included patients with toxicity grade 3 or greater during study treatment</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Subset characterization (histological subtypes)</measure>
    <time_frame>Immediately after surgery</time_frame>
    <description>Distribution of different histopathological subsets of Triple Negative Breast Cancer (TNBC).</description>
  </other_outcome>
  <other_outcome>
    <measure>Subset characterization (germline mutations)</measure>
    <time_frame>Immediately after surgery</time_frame>
    <description>Distribution of subsets of Triple Negative Breast Cancer (TNBC) associated with different inherited breast cancer genes (BRCA1, BRCA2, PALB2, TP53, CHEK2, ATM, RAD51 C and RAD51D).</description>
  </other_outcome>
  <other_outcome>
    <measure>Subset characterization (somatic mutations)</measure>
    <time_frame>Immediately after surgery</time_frame>
    <description>Distribution of subsets of Triple Negative Breast Cancer (TNBC) associated with somatic mutations, (Eg BRCA1, BRCA2, PALB2, TP53, and other).</description>
  </other_outcome>
  <other_outcome>
    <measure>Subset characterization (epigenetic alterations)</measure>
    <time_frame>Immediately after surgery</time_frame>
    <description>Distribution of different subsets of Triple Negative Breast Cancer (TNBC) defined based on epigenetic alterations associated with silencing of BRCA1, RAD51 and related HRD-associated genes.</description>
  </other_outcome>
  <other_outcome>
    <measure>pCR and long term outcome in histologic subsets of TNBC</measure>
    <time_frame>Immediately after surgery</time_frame>
    <description>pCR rate in different histopathological subsets of Triple Negative Breast Cancer (TNBC).</description>
  </other_outcome>
  <other_outcome>
    <measure>pCR and long term outcome in subsets of TNBC defined based on occurrence of germline genetic alterations</measure>
    <time_frame>Immediately after surgery</time_frame>
    <description>pCR rate in subsets of Triple Negative Breast Cancer (TNBC) associated with different inherited breast cancer genes (BRCA1, BRCA2, PALB2, TP53, CHEK2, ATM, RAD51 C and RAD51D).</description>
  </other_outcome>
  <other_outcome>
    <measure>pCR and long term outcome in subsets of TNBC defined based on occurrence of somatic genetic alterations</measure>
    <time_frame>Immediately after surgery</time_frame>
    <description>pCR rate in subsets of Triple Negative Breast Cancer (TNBC) associated with somatic mutations, (Eg BRCA1, BRCA2, PALB2, TP53, and other).</description>
  </other_outcome>
  <other_outcome>
    <measure>pCR and long term outcome in subsets of TNBC defined on epigenetic alterations</measure>
    <time_frame>Immediately after surgery</time_frame>
    <description>pCR rate in different subsets of Triple Negative Breast Cancer (TNBC) based on epigenetic alterations associated with silencing of BRCA1, RAD51 and related HRD-associated genes.</description>
  </other_outcome>
  <other_outcome>
    <measure>pCR and long term outcome in immun marker defined subsets of TNBC</measure>
    <time_frame>Immediately after surgery</time_frame>
    <description>pCR rate in subsets of Triple Negative Breast Cancer (TNBC) associated with the expression of PDL1.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">820</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Triple Negative Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>Arm A (Platinum-based dose dense EC):</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Two-weekly epirubicin/cyclophosphamide (EC) x 4 (epirubicin 90 mg/m2 and cyclophosphamide 600 mg/m2), followed after a three-week interval by three-weekly carboplatin x 4 (AUC = 5) together with weekly paclitaxel x 12 (80 mg/m2).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (Platinum-based with capecitabine):</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three-weekly cyclophosphamide/epirubicin/capecitabine (CEX) (epirubicin 75 mg/m2, cyclophosphamide 600 mg/m2 and capecitabine 900 mg/m2) x 4, followed after a three-week interval by three-weekly carboplatin x 4 (AUC = 5) together with weekly paclitaxel x 12 (80 mg/m2).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epirubicin, cyclophosphamide, paclitaxel, carboplatin</intervention_name>
    <description>Cytotoxic agents.</description>
    <arm_group_label>Arm A (Platinum-based dose dense EC):</arm_group_label>
    <other_name>anthracycline, taxane, platinum</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epirubicin, cyclophosphamide, capecitabine, paclitaxel, carboplatin</intervention_name>
    <description>Cytotoxic agents.</description>
    <arm_group_label>Arm B (Platinum-based with capecitabine):</arm_group_label>
    <other_name>anthracycline, taxane, antimetabolite, platinum</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed written informed consent approved by the Ethical Review Board (IRB).

          2. Age 18 to 75 years.

          3. Histologically confirmed unilateral adenocarcinoma of the breast where neoadjuvant
             chemotherapy followed by definitive surgery is planned.

          4. Node positive disease (N1-3) or if clinically N0 Tumor size &gt;20 mm.

          5. ER negative tumor defined by at least one the following:

               1. ER &lt; 1% cells positive by immuno-histochemistry (IHC)

               2. ER &lt; 10% cells positive by IHC and progesterone receptor) progesterone receptor
                  (PgR) &lt; 10% cells positive by IHC

          6. Human Epidermal Growth Factor Receptor2 (HER2)-normal tumor defined by at least one of
             the following:

               1. HER2 0 or 1+ by immunohistochemistry

               2. HER2 2+ by IHC and HER2 to centromere 17 ratio &lt; 2.0 and/or less than 6 copies by
                  in situ hybridization [ISH]).

             Comment: Patients with 3+ IHC for HER2 will not be included irrespective of the
             outcome of in situ hybridization (ISH)-analysis.

          7. Consent for germline mutation screening for BRCA1, BRCA2 and other inherited breast
             cancer associated genes.

          8. World Health Organization (WHO) performance status 0 or 1.

          9. Negative pregnancy test in women of childbearing potential (premenopausal or &lt;12
             months of amenorrhea post-menopause and who have not undergone surgical
             sterilization).

         10. Willingness by the patient to undergo treatment according to the protocol and study
             related procedures.

        Exclusion Criteria:

          1. Clinical or radiological signs of metastatic disease.

          2. Clinically inflammatory breast cancer

          3. History of other malignancy within the last 5 years, except for carcinoma in situ of
             the cervix or non-melanoma skin cancer.

          4. Previous chemotherapy for cancer or other malignant disease.

          5. Charlson comorbidity index, excluding score for malignancy: (CCI) &gt; 2, Comment: In
             patients 70-75 a CCI = 3 is allowed, see appendix B.

          6. Inadequate organ function, suggested by the following laboratory results:

             a. Absolute neutrophil count &lt; 1,5 x 109/l b Platelet count &lt; 100 x 109/l c
             Haemoglobin &lt; 90 g/L d Total bilirubin greater than the upper limit of normal (ULN)
             unless the patient has documented Gilbert´s syndrome e Aspartate Aminotransferase
             (AST), (SGOT) and/or Alanine Aminotransferase (ALT), (SGPT) &gt; 2,5 x ULN f AST (SGOT)
             and/or ALT (SGPT) &gt; 1,5 x ULN with concurrent serum alkaline phosphatase (ALP) &gt; 2,5 x
             ULN g Serum creatinine clearance &lt; 50 mL/min

          7. Concurrent peripheral neuropathy of grade 3 or greater (NCI-CTCAE, Version 5.0)

          8. Patient who is actively breast feeding.

          9. Assessed by the Investigator to be unable or unwilling to comply with the requirements
             of the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Niklas Loman, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Lund University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Niklas Loman, MD, PhD</last_name>
    <phone>+46 46 17 75 20</phone>
    <email>niklas.loman@med.lu.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lina Zander, RN</last_name>
    <phone>+46 46 17 78 29</phone>
    <email>nordictrip.onkologi@skane.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Södra Älvsborgs Hospital</name>
      <address>
        <city>Borås</city>
        <zip>501 82</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zakaria Einbeigi, MD, PhD</last_name>
      <phone>+46 33 616 10 00</phone>
      <email>zakaria.einbeigi@oncology.gu.se</email>
    </contact>
    <investigator>
      <last_name>Zakaria Einbeigi, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gävle hospital, Department of Oncology</name>
      <address>
        <city>Gävle</city>
        <zip>803 24</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Per Edlund, MD, PhD</last_name>
      <phone>+46 26 15 40 00</phone>
      <email>per.edlund@regiongavleborg.se</email>
    </contact>
    <investigator>
      <last_name>Per Edlund, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital, Department of Oncology</name>
      <address>
        <city>Göteborg</city>
        <zip>413 46</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Barbro Linderholm, MD, PhD</last_name>
      <phone>+46 31 342 10 00</phone>
      <email>barbro.linderholm@ki.se</email>
    </contact>
    <investigator>
      <last_name>Barbro Linderholm, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Halmstad Hospital, Department of Surgery</name>
      <address>
        <city>Halmstad</city>
        <zip>302 33</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alaa Haidar, MD, PhD</last_name>
      <phone>+46 35 13 10 00</phone>
      <email>alaa.haidar@regionhalland.se</email>
    </contact>
    <investigator>
      <last_name>Alaa Haidar, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ryhov Hospital</name>
      <address>
        <city>Jönköping</city>
        <zip>551 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ida Spång Rosén, MD</last_name>
      <phone>+46 10 241 00 00</phone>
      <email>ida.spang.rosen@rjl.se</email>
    </contact>
    <investigator>
      <last_name>Ida Spång Rosén, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karlstad Hospital</name>
      <address>
        <city>Karlstad</city>
        <zip>652 30</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kilian Bachmeier, MD</last_name>
      <phone>+46 72 70 39 754</phone>
      <email>kilian.bachmeier@regionvarmland.se</email>
    </contact>
    <investigator>
      <last_name>Kilian Bachmeier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Linköping University Hospital</name>
      <address>
        <city>Linköping</city>
        <zip>581 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nina Letter al-Ayoubi, MD</last_name>
      <phone>+46 10 103 00 00</phone>
      <email>nina.letter.al-ayoubi@regionostergotland.se</email>
    </contact>
    <investigator>
      <last_name>Nina Letter al-Ayoubi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Skåne University Hospital, Department of Oncology</name>
      <address>
        <city>Malmö</city>
        <zip>20501</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Niklas Loman, MD, PhD</last_name>
      <phone>+46 46 17 75 20</phone>
      <email>niklas.loman@med.lu.se</email>
    </contact>
    <contact_backup>
      <last_name>Rosita Nordkvist, RN</last_name>
      <phone>+46 40 33 28 42</phone>
      <email>rosita.nordkvist@skane.se</email>
    </contact_backup>
    <investigator>
      <last_name>Niklas Loman, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Capio S:t Göran Hospital, Department of Oncology</name>
      <address>
        <city>Stockholm</city>
        <zip>112 19</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jenny Bergqvist, MD, PhD</last_name>
      <phone>+46 8 587 010 00</phone>
      <email>jenny.bergkvist@capiostgoran.se</email>
    </contact>
    <investigator>
      <last_name>Jenny Bergkvist, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Södersjukhuset, Department of Oncology</name>
      <address>
        <city>Stockholm</city>
        <zip>118 61</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Camilla Wendt, MD, PhD</last_name>
      <phone>+46 8 616 10 00</phone>
      <email>cailla.wendt@sll.se</email>
    </contact>
    <investigator>
      <last_name>Camilla Wendt, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sundsvall hospital</name>
      <address>
        <city>Sundsvall</city>
        <zip>851 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anna-Karin Wennstig, MD, PhD</last_name>
      <phone>+46 60 18 25 40</phone>
      <email>annakarin.wennstig@lvn.se</email>
    </contact>
    <investigator>
      <last_name>Anna-Karin Wennstig, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norrland University Hospital, Department of Oncology</name>
      <address>
        <city>Umeå</city>
        <zip>907 37</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne Andersson, MD, PhD</last_name>
      <phone>+46 90 785 00 00</phone>
      <email>anne.andersson@umu.se</email>
    </contact>
    <investigator>
      <last_name>Anne Andersson, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Academical Hospital, Department of Oncology</name>
      <address>
        <city>Uppsala</city>
        <zip>753 09</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Henrik Lindman, MD, PhD</last_name>
      <phone>+46 18 611 00 00</phone>
      <email>henrik.lindman@igp.uu.se</email>
    </contact>
    <investigator>
      <last_name>Henrik Lindman, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Västmanlands Hopsital Västerås</name>
      <address>
        <city>Västerås</city>
        <zip>721 89</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Helena Granstam Björnklett, MD, PhD</last_name>
      <phone>+46 21 30 00</phone>
      <email>helena.granstam-bjorneklett@regionvastmanland.se</email>
    </contact>
    <investigator>
      <last_name>Helena Granstam Björneklett, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Växjö Hospital, Department of Oncology</name>
      <address>
        <city>Växjö</city>
        <zip>352 34</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ulrik Narbe, MD, PhD</last_name>
      <phone>+46 470 58 80 00</phone>
      <email>ulrik.narbe@med.lu.se</email>
    </contact>
    <investigator>
      <last_name>Ulrik Narbe, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Örebro University Hospital, Department of Oncology</name>
      <address>
        <city>Örebro</city>
        <zip>701 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antonis Valachis, MD, PhD</last_name>
      <phone>+46 19 602 10 00</phone>
      <email>antonis.valachis@igp.uu.se</email>
    </contact>
    <investigator>
      <last_name>Antonis Valachis, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 2, 2019</study_first_submitted>
  <study_first_submitted_qc>April 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2020</study_first_posted>
  <last_update_submitted>April 2, 2020</last_update_submitted>
  <last_update_submitted_qc>April 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast neoplasms</keyword>
  <keyword>Triple negative breast neoplasms</keyword>
  <keyword>Neoadjuvant treatment</keyword>
  <keyword>Translational research</keyword>
  <keyword>Pathologic response</keyword>
  <keyword>Pathologic complete response</keyword>
  <keyword>epirubicin</keyword>
  <keyword>cyclophosphamide</keyword>
  <keyword>paclitaxel</keyword>
  <keyword>carboplatin</keyword>
  <keyword>capecitabine</keyword>
  <keyword>Survival outcomes</keyword>
  <keyword>Homologous repair deficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
    <mesh_term>Taxane</mesh_term>
    <mesh_term>Antimetabolites</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 24, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/69/NCT04335669/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

